The global dermatology market is set to boom from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%, GBI Research reports.

This rise will occur despite the patent expirations of many marketed monoclonal antibodies (mAbs). Growth will be driven by a strong late-stage pipeline, which includes several highly targeted therapies, for major skin disorders, including atopic dermatitis, acne vulgaris and rosacea.

Specifically, Regeneron/Sanofi’s dupilumab is expected to bring about a paradigm shift in the treatment moderate-to-severe atopic dermatitis. At the same time, the use of older systemic immunosuppressants in dermatology is likely to decrease once biologics for other key indications besides psoriasis enter the market in 2016 and beyond, the report states.

Key market players, namely Johnson & Johnson, Abide, Amgen, Novartis, and Roche, are expected to maintain their strong market shares throughout the forecast period, despite the fact that many of the approaching patent expiries – especially AbbVie’s Humira and Johnson & Johnson’s Remicade – will affect these companies directly, GBI reports.